Download Medical Notes on Orphan Drugs in the United States - Exclusivity, Pricing and Treated Populations

Orphan Drugs in the United States - Exclusivity, Pricing and Treated Populations Medical Notes

About This Presentation

Description:This report titled, “Orphan Drugs in the United States - Exclusivity, Pricing and Treated Populations” is by the IQVIA Institute and is an analysis of the orphan drug market. The report explores this topic of orphan drugs’ orphan and non-orphan indication approvals and their associated patent and market exclusivities. The report also examines orphan drug pricing relative to patient numbers, how those prices change over time, and – in a first-of-its-kind comprehensive analysis – compares current disease epidemiology to the number of treated patients to demonstrate the challenges in bringing orphan drugs to patients even after they are approved.

Tags:Healthcare, Orphan Drugs, United States, market, pricing, disease epidemiology

Published on: Jul 20, 2020 | Views : 1277 | Downloads : 0

Comment

Transcript

No transcript available for this presentation

User Presentation
Related Presentations

Understanding Neuromuscular Disease Care Current State and Future Prospects

About : I am a passionate medical marketing professional with hands on experience in healthcare digital marketing.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : India
Website :

Understanding Neuromuscular Disease Care Current State and Future Prospects

Health Care in Developing Countries - Challenges and Opportunities

PERFECT HEALTH FOUNDED ON ANCIENT TRADITIONS AND LEADING RESEARCH - Spa

Understanding Medicine Spending in Australia - Trends and dynamics in healthcare and medicine spending

The Global Use of Medicine in 2019 and Outlook to 2023

Pharma 2020 Virtual R and D a paper on the future of the pharmaceutical industry

Evaluate Vantage 2020 Preview – A Report on Pharmaceutical Industry

Understanding Medicine Spending in Australia - Trends and dynamics in healthcare and medicine spending

Biopharma Companies Join Forces to Fight COVID-19

The financialisation of Big Pharma

HEALTH A TO Z